Additional Pharmacologic Options for Primary Insomnia When CBT-I Is Unavailable
When CBT-I is not accessible, the American Academy of Sleep Medicine recommends short- or intermediate-acting benzodiazepine receptor agonists (BzRAs) or ramelteon as first-line pharmacotherapy, with specific agent selection based on whether the patient has sleep-onset, sleep-maintenance, or combined insomnia. 1
First-Line Pharmacologic Agents by Insomnia Phenotype
For Sleep-Onset Insomnia
Zaleplon 10 mg (5 mg if age ≥65 years) has an ultrashort half-life (~1 hour) providing rapid sleep initiation with minimal next-day sedation, making it ideal for sleep-onset difficulty. 1, 2
Zolpidem 10 mg (5 mg if age ≥65 years) reduces sleep-onset latency by approximately 25 minutes and increases total sleep time by 29 minutes; take within 30 minutes of bedtime with at least 7 hours remaining before awakening. 1
Ramelteon 8 mg is a melatonin-receptor agonist with no abuse potential, no DEA scheduling, and no withdrawal symptoms, making it particularly appropriate for patients with substance-use history. 1, 2
For Sleep-Maintenance Insomnia
Low-dose doxepin 3–6 mg is the preferred first-line option for sleep-maintenance problems, reducing wake after sleep onset by 22–23 minutes with minimal anticholinergic effects at hypnotic doses and no abuse potential. 1, 2
Suvorexant 10 mg (orexin-receptor antagonist) reduces wake after sleep onset by 16–28 minutes through a completely different mechanism than benzodiazepine-type agents, with lower risk of cognitive and psychomotor impairment. 3, 1, 4
For Combined Sleep-Onset and Maintenance Insomnia
Eszopiclone 2–3 mg (1 mg if age ≥65 years or hepatic impairment) improves both sleep onset and maintenance, increasing total sleep time by 28–57 minutes with moderate-to-large improvements in subjective sleep quality. 1
Temazepam 15 mg is suggested for both sleep-onset and sleep-maintenance insomnia, though it carries higher risks than non-benzodiazepine options. 1
Second-Line Options When First-Line Agents Fail
If the initial BzRA is ineffective after 1–2 weeks, switch to an alternative agent within the same class (e.g., zaleplon → zolpidem for onset; doxepin → suvorexant for maintenance) rather than adding a second hypnotic. 1
Daridorexant (another orexin-receptor antagonist) may be continued for up to 3 months or longer in selected patients when other agents have failed. 1, 5
Sedating antidepressants such as low-dose doxepin or mirtazapine may be considered as third-line options, especially when comorbid depression or anxiety is present. 1
Critical Dosing Adjustments for Older Adults
For patients ≥65 years, maximum doses must be reduced: zolpidem ≤5 mg, eszopiclone ≤2 mg, zaleplon ≤5 mg, doxepin ≤6 mg, due to increased sensitivity and fall risk. 1
Low-dose doxepin 3 mg and ramelteon 8 mg are the safest first-line choices for older adults because they carry minimal fall risk and cognitive impairment. 1
Medications Explicitly NOT Recommended
Trazodone should NOT be used for primary insomnia because it yields only a ~10-minute reduction in sleep latency with no improvement in subjective sleep quality, and harms outweigh benefits. 1, 2
Over-the-counter antihistamines (diphenhydramine, doxylamine) are contraindicated due to lack of efficacy, strong anticholinergic effects (confusion, urinary retention, falls, daytime sedation, delirium), and tolerance development within 3–4 days. 1, 2
Antipsychotics (quetiapine, olanzapine) must be avoided for insomnia because evidence is weak and they carry significant risks including weight gain, metabolic syndrome, extrapyramidal symptoms, and increased mortality in elderly patients. 1
Traditional benzodiazepines (lorazepam, clonazepam, diazepam) should not be used routinely due to long half-lives causing drug accumulation, daytime sedation, higher fall and cognitive-impairment risk, and associations with dementia and fractures. 1
Melatonin supplements are not recommended for chronic insomnia, producing only a ~9-minute reduction in sleep latency with insufficient evidence. 1, 2
Safety Monitoring and Duration
Reassess patients after 1–2 weeks to evaluate sleep-onset latency, total sleep time, nocturnal awakenings, daytime functioning, and adverse effects such as morning sedation, cognitive impairment, and complex sleep behaviors. 1
FDA labeling limits hypnotic use to ≤4 weeks for acute insomnia; evidence for longer durations is insufficient, and continuation beyond this period requires documented rationale and periodic reassessment. 3, 1
All benzodiazepine-receptor agonists carry FDA warnings for complex sleep behaviors (sleep-driving, sleep-walking, sleep-eating); discontinue immediately if these occur. 1
If insomnia persists beyond 7–10 days despite appropriate treatment, evaluate for underlying sleep disorders such as obstructive sleep apnea, restless-legs syndrome, or circadian-rhythm disorders. 1, 4
Treatment Algorithm When CBT-I Is Unavailable
Identify the primary insomnia phenotype: sleep-onset difficulty, sleep-maintenance difficulty, or combined symptoms. 1, 2
Select the appropriate first-line agent using the formulary decision tree above, with age-adjusted dosing for patients ≥65 years. 1
Prescribe at the lowest effective dose for the shortest necessary duration (generally ≤4 weeks), and counsel patients about expected effects and safety warnings. 1
Reassess after 1–2 weeks: if response is inadequate, switch to an alternative agent within the same class rather than adding a second hypnotic. 1
If multiple first-line agents fail, consider second-line options (orexin antagonists, sedating antidepressants) or evaluate for comorbid sleep disorders. 1
Common Pitfalls to Avoid
Do not prescribe trazodone, OTC antihistamines, or antipsychotics for primary insomnia despite their common off-label use; they lack efficacy and carry significant safety concerns. 1, 2
Do not use adult dosing in older adults; age-adjusted dosing is mandatory to reduce fall risk. 1
Do not combine multiple sedating agents (e.g., adding a benzodiazepine to a Z-drug), which markedly increases risk of respiratory depression, cognitive impairment, falls, and complex sleep behaviors. 1
Do not continue pharmacotherapy beyond 4 weeks without periodic reassessment (every 2–4 weeks) to evaluate efficacy, side effects, and ongoing need. 1
Do not prescribe agents without matching their pharmacologic profile to the specific insomnia phenotype (e.g., using zaleplon for maintenance rather than onset). 1